CLOVERLEAF BIO, INC. — Department of Health and Human Services SBIR: FY25 CONCEPT AWARD: DEVELOPMENT OF ENGINEERED TRNA THERAPEUTICS FOR CLEAR CELL RENAL CELL
CLOVERLEAF BIO, INC. — SBIR award from Department of Health and Human Services.
SBIR award competitive context
- Public SBIR obligation from Department of Health and Human Services to CLOVERLEAF BIO, INC.. Use agency + tech-domain links below to map the broader competitive field.
- Obligated amount $300,000. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Cloverleaf Bio, Inc. received a $300,000 NIH SBIR concept award to develop engineered tRNA therapeutics for treating clear cell renal cell carcinoma, a common kidney cancer. The project focuses on creating new RNA-based treatments to address this disease.
- Amount
- $300,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- CT
- Period
- 2025-09-15 → 2027-09-14
Technology domains
Description
SBIR FY25 CONCEPT AWARD: DEVELOPMENT OF ENGINEERED TRNA THERAPEUTICS FOR CLEAR CELL RENAL CELL CARCINOMA